Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NRX Pharmaceuticals (NRXP) Income from Continuing Operations (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Income from Continuing Operations for 2 consecutive years, with 5291000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 117.92% to 5291000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 16884000.0 through Dec 2025, up 9.65% year-over-year, with the annual reading at 16883000.0 for FY2025, 9.66% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 5291000.0 at NRX Pharmaceuticals, down from 4022000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 2428000.0 in Q4 2024, with the low at 7043000.0 in Q2 2024.